Avulux lands FDA de novo classification for light-sensitive migraine lenses
Avulux’s lens technology uses a optical filters to block up to 97% of blue, amber, and red light while letting soothing green light through.
Avulux’s lens technology uses a optical filters to block up to 97% of blue, amber, and red light while letting soothing green light through.
With regulatory conditions tightening around climate impact and environmental persistence of medical propellants, HFA-152a is a practical route to maintain clinical performance, patient outcomes and supply continuity of inhalers. However,...
The medical devices industry continues to be a hotbed of patent innovation. Activity is driven by increased need for homecare,...
UK government champions healthtech through new NHS access programme
Intuitive Surgical expands platforms despite market headwind
The increased importance of safety for wearable devices
What does the EU Data Act mean for businesses?